{"id":"NCT01579474","sponsor":"Boehringer Ingelheim","briefTitle":"Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial","officialTitle":"Safety, Efficacy and Pharmacokinetics of BI 201335 NA in Patient With Genotype 1 Chronic Hepatitis C Virus Infection in Combination With Pegylated Interferon Alfa-2b and Ribavirin - Cohort 1 for Treatment-naive Patients: Randomised, Double-blind Part of BI 201335 NA for 12 or 24 Weeks - Cohort 2 for Treatment-experienced Patients: Open-label Part of BI 201335 NA for 24 Weeks","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-04","primaryCompletion":"2013-12","completion":"2013-12","firstPosted":"2012-04-18","resultsPosted":"2015-08-03","lastUpdate":"2015-08-03"},"enrollment":131,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C"],"interventions":[{"type":"DRUG","name":"BI 201335 high dose","otherNames":[]},{"type":"DRUG","name":"BI 201335 low dose","otherNames":[]},{"type":"DRUG","name":"BI 201335 high dose","otherNames":[]},{"type":"DRUG","name":"BI 201335 high dose","otherNames":[]}],"arms":[{"label":"1. BI 201335 low dose plus PegIFN/RBV","type":"EXPERIMENTAL"},{"label":"2. BI 201335 high dose plus PegIFN/RBV","type":"EXPERIMENTAL"},{"label":"3. BI 201335 high dose plus PegIFN/RBV","type":"EXPERIMENTAL"},{"label":"4. BI 201335 high dose plus PegIFN/RBV","type":"EXPERIMENTAL"}],"summary":"The aim of this trial is to evaluate the safety and efficacy of BI 201335 given for 12 or 24 weeks in combination with PegIFN alfa-2b/RBV given for 24 or 48 weeks in chronic genotype 1 hepatitis C virus infected treatment-na√Øve and treatment-experienced Japanese patients","primaryOutcome":{"measure":"Number of Patients With Investigator Defined Drug-related Adverse Events","timeFrame":"Up to 52 weeks","effectByArm":[{"arm":"Faldaprevir 120 mg q.d - Cohort I","deltaMin":43,"sd":null},{"arm":"Faldaprevir 240 mg q.d - Cohort I","deltaMin":43,"sd":null},{"arm":"Faldaprevir 240 mg q.d - Cohort II","deltaMin":44,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":24,"countries":["Japan"]},"refs":{"pmids":["27153246"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":44},"commonTop":["Pyrexia","Nausea","Rash","Vomiting","Diarrhoea"]}}